5%白蛋白联合生理盐水与单用生理盐水对重症患者大容量复苏结局的影响
这项回顾性队列研究纳入13家医院ICU中接受大容量复苏(24小时内>60 mL/kg)的18,629例危重患者,比较5%白蛋白联合生理盐水与单用0.9%生理盐水。在多因素回归中,5%白蛋白与30天死亡率降低相关(H08队列OR 0.65,95%CI 0.49-0.85;H15队列OR 0.52,95%CI 0.44-0.62),但与急性肾损伤发生率升高相关(H08 OR 1.98,95%CI 1.56-2.51;H15 OR 1.75,95%CI 1.58-1.95)。然而5%白蛋白与持续性急性肾损伤无关,且与30、90、365天主要不良肾脏事件减少相关。倾向性匹配分析证实了死亡率和急性肾损伤的类似关联。
要点
- 大容量复苏(24小时内>60 mL/kg)时加用5%白蛋白与30天死亡率降低相关:H08队列OR 0.65(95%CI 0.49-0.85),H15队列OR 0.52(95%CI 0.44-0.62)。
- 5%白蛋白与急性肾损伤(任何分期)发生率升高相关:H08队列OR 1.98(95%CI 1.56-2.51),H15队列OR 1.75(95%CI 1.58-1.95)。
- 5%白蛋白未增加持续性急性肾损伤,且与30、90、365天主要不良肾脏事件减少相关。
- 倾向性匹配分析证实5%白蛋白与死亡率降低及急性肾损伤升高的关联类似。
- 该证据来自回顾性队列,不能直接推断因果关系,床旁决策需结合患者具体情况。
适用人群与场景
- 纳入13家医院ICU中需要大容量复苏(24小时内>60 mL/kg)的危重患者,共18,629例;分析前排除大容量复苏前已存在急性肾损伤的患者。
- 场景为ICU内大容量复苏,非院前或急诊抢救室。
诊断标准与关键阈值
- 大容量复苏定义:24小时内输液量>60 mL/kg。
- 急性肾损伤诊断标准原文未提及具体分期标准。
处置流程与药物剂量
- 原文未提及具体给药剂量、途径、频次或目标值;干预为5%白蛋白联合生理盐水 versus 单用0.9%生理盐水。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 干预与对照:5%白蛋白联合生理盐水 vs 单用0.9%生理盐水。
- 主要终点:30天死亡率——5%白蛋白组H08队列OR 0.65(95%CI 0.49-0.85,p=0.002),H15队列OR 0.52(95%CI 0.44-0.62,p<0.0001)。
- 急性肾损伤(任何分期)——5%白蛋白组H08队列OR 1.98(95%CI 1.56-2.51,p<0.001),H15队列OR 1.75(95%CI 1.58-1.95,p<0.001)。
- 5%白蛋白与持续性急性肾损伤无关,且与30、90、365天主要不良肾脏事件减少相关;倾向性匹配分析证实类似关联。
证据类型、等级与局限
- 证据类型:回顾性队列研究;原文未给出证据等级或推荐强度。
- 局限:回顾性设计,可能存在残余混杂;原文未提及单中心或多中心以外的其他局限。
对床旁实践的改变
- 在大容量复苏(24小时内>60 mL/kg)的ICU危重患者中,加用5%白蛋白可能降低30天死亡率及主要不良肾脏事件,但需警惕急性肾损伤发生率升高(任何分期),尽管未增加持续性肾损伤。
- 该证据为回顾性队列,不能作为常规推荐5%白蛋白的依据,临床决策需个体化。
- 原文未提供具体剂量、疗程或目标值,不适用于指导具体给药方案。
指南或共识出处
- 原文未提及指南或共识出处;文献来源为Crit Care Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare 5% albumin with 0.9% saline for large-volume resuscitation (> 60 mL/Kg within 24 hr), on mortality and development of acute kidney injury.
DESIGN: Retrospective cohort study.
SETTING: Patients admitted to ICUs in 13 hospitals across Western Pennsylvania. We analyzed two independent cohorts, the High-Density Intensive Care databases: High-Density Intensive Care-08 (July 2000 to October 2008, H08) and High-Density Intensive Care-15 (October 2008 to December 2014, H15).
PATIENTS: Total of 18,629 critically ill patients requiring large-volume resuscitation.
INTERVENTIONS: Five percent of albumin in addition to saline versus 0.9% saline.
MEASUREMENTS AND MAIN RESULTS: After excluding patients with acute kidney injury prior to large-volume resuscitation, 673 of 2,428 patients (27.7%) and 1,814 of 16,201 patients (11.2%) received 5% albumin in H08 and H15, respectively. Use of 5% albumin was associated with decreased 30-day mortality by multivariate regression in H08 (odds ratio 0.65; 95% CI 0.49-0.85; p = 0.002) and in H15 (0.52; 95% CI 0.44-0.62; p < 0.0001) but was associated with increased acute kidney injury in H08 (odds ratio 1.98; 95% CI 1.56-2.51; p < 0.001) and in H15 (odds ratio 1.75; 95% CI 1.58-1.95; p < 0.001). However, 5% albumin was not associated with persistent acute kidney injury and resulted in decreased major adverse kidney event at 30, 90, and 365 days. Propensity matched analysis confirmed similar associations with mortality and acute kidney injury.
CONCLUSIONS: During large-volume resuscitation, 5% albumin was associated with reduced mortality and major adverse kidney event at 30, 90, and 365 days. However, a higher rate of acute kidney injury of any stage was observed that did not translate into persistent renal dysfunction.
参考来源
- Gomez H, Priyanka P, Bataineh A, et al. Effects of 5% Albumin Plus Saline Versus Saline Alone on Outcomes From Large-Volume Resuscitation in Critically Ill Patients. Crit Care Med. 2021. PMID: 33165027. doi:10.1097/CCM.0000000000004706
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。